|
Mechanisms of prenatal opioid exposure on brain and behavior |
1R01DA050871-01A1 |
|
NIDA |
2022 |
|
Role of disability and pain in opioid overdose: mechanism and risk mitigation |
1R01DA053243-01A1 |
|
NIDA |
2022 |
|
Impact of Medicare Part D opioid safety policies on disabled beneficiaries before and during the COVID-19 pandemic |
1R01DA055131-01 |
|
NIDA |
2022 |
|
Improving MOUD Access, Opioid-Related Outcomes and Equity Among Medicare Beneficiaries with Disability |
1R01DA057568-01 |
|
NIDA |
2022 |
|
Neurocognitive implications of cannabidiol (CBD) while aging with HIV |
1R03DA057146-01 |
|
NIDA |
2022 |
|
Social determinants of substance use disorder treatment outcomes in a vulnerable population |
1R21DA055229-01 |
|
NIDA |
2022 |
|
A telehealth tDCS approach to decrease cannabis use: Towards reducing multiple sclerosis disability in multiple sclerosis |
1R21DA055427-01 |
|
NIDA |
2022 |
|
Psychostimulants, Attention Deficit and Basal Ganglia Disorders |
1R21DA055980-01 |
|
NIDA |
2022 |
|
Dissecting functional roles of MeCP2 condensates in neurons with chemogenetic tools |
1R21DA056293-01 |
|
NIDA |
2022 |
|
A pilot study of ambulatory Heart Rate Variability Biofeedback for substance use disorder |
1R21DA056468-01 |
|
NIDA |
2022 |